The Role of hCG in Thawed Embryo Transfer

Phase 4

Not yet recruiting

• Conditions: Infertility (IVF Patients)
• Interventions: Drug: HCG injection; Other: No intervention

• Registration Number: NCT07004192
• Lead Sponsor: Fertility Center of Las Vegas

Brief Summary

This prospective randomized trial will assess the relevance, if any, of a corpus luteum induced by hCG in transfers of thawed embryos.

Detailed Description

The current study is designed to carefully isolate the effect of a corpus luteum by ensuring that the presence or absence of a corpus luteum is the only difference between two study arms. This should be reliably achieved by administering an injection of hCG in one study arm, while the other study arm has identical treatment except for omitting the hCG.

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-27
• Study First Submitted QC: 2025-05-27
• Last Update Submitted: 2025-05-27
• Study Start: 2025-06-02
• Study First Posted: 2025-06-04
• Last Update Posted: 2025-06-04
• Primary Completion: 2027-12-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: Female
• Target Recruitment: 220

Inclusion Criteria

1. Female adult expecting to receive transfer of a thawed embryo.
2. At least one available frozen blastocyst of transferrable quality.
3. Non-menopausal female with at least one antral follicle.
4. Use of pre-implantation genetic testing (PGT), embryos derived from donor oocytes and/or donor sperm, a gestational carrier, and history of prior transfer(s) regardless of outcome are allowed.
5. Subsequent embryo transfers after failed transfers under this study are allowed, but not after a transfer that has resulted in ongoing pregnancy at ten weeks gestation under this study.

Exclusion Criteria

1. Minors (age<18 years).
2. Use of embryo(s) frozen at another center.
3. Patient insistent on transfer of two embryos.
4. Patient or partner unable to provide informed consent in English.
5. Patient already enrolled in any other research study for her embryo transfer.
6. History of anti-phospholipid syndrome or any other indication for use of Lovenox in pregnancy.
7. Patient for whom the physician assesses this protocol is inappropriate or unsafe.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
hCG Group	HCG injection	This group receives one injection of hCG.
No hCG Group	No intervention	This arm receives no hCG.

Primary Outcome Measures

Name	Time	Method
Blood pressure	Third trimester of pregnancy	Mean arterial pressure measured in third trimester of pregnancy

Trial Locations

Locations (1)

Fertility Center of Las Vegas; 🇺🇸 Las Vegas, Nevada, United States